IFM Therapeutics

At IFM Therapeutics, we are transforming treatment for inflammatory diseases and cancer by developing drugs that target the innate immune system.

[IFM Therapeutics @IFMThera]

Today we announced that @Novartis has exercised an option to acquire all outstanding capital stock of IFM Due, our subsidiary focused on developing novel STING antagonists to address a variety of serious inflammation-driven diseases.

[IFM Therapeutics @IFMThera]

With the progression of 4 novel programs to the clinic and the closing of 3 major deals, we’re so proud of how far we’ve come in fewer than 8 years: https://t.co/vQykz5rDeQ

[IFM Therapeutics @IFMThera]

With the acquisition of IFM Due by Novartis, we have achieved 3 deals comprising 4 programs that have advanced to the clinic. With only $58 million of invested capital, this work has resulted in $750 million in realized returns and ~$4 billion in potential future milestones.

[IFM Therapeutics @IFMThera]

The acquisition of IFM Due by Novartis marks our second major deal with Novartis. IFM Tre’s lead candidate, acquired in 2019, is now in multiple phase 2 trials.

We’re excited about the potential impact of our work for patients who need new therapies for #inflammatory diseases.

[IFM Therapeutics @IFMThera]

At IFM we're developing drugs that precisely target components of the body's master regulator of subsequent immune activity—the #innateimmune system. Innate immune biology offers various clinical opportunities across a variety of therapeutic areas. Learn more:

[IFM Therapeutics @IFMThera]

Do you know what happens when an NLR protein becomes activated? Inhibiting these pattern recognition receptors may bring more effective treatment options for patients with #inflammatory diseases. Learn more: https://t.co/f9zuIKHUfy #NLRP3 #NLRP1 #innateimmunity

[IFM Therapeutics @IFMThera]

#DYK IFM was founded in 2015? Since then, we've advanced 3 novel programs from start to the clinic that target the #innateimmune system and provide new treatment options. Read our story: https://t.co/lYukCSlPdW

[IFM Therapeutics @IFMThera]

Results from a recent study in Nature indicate that #NLRP1, Casp1 and Casp6 represent rational therapeutic targets against cognitive impairment and inflammation in #AlzheimersDisease. Read more:

[IFM Therapeutics @IFMThera]

Mutations that activate the #cGAS/STING pathway can cause a variety of #autoimmune and inflammatory diseases. Within our IFM Due subsidiary, we're working to develop therapies for serious conditions driven by this pathway. Learn more:

[IFM Therapeutics @IFMThera]

Cheers to the New Year! 2021 has shown us the impact the global science community can make to change and save lives. We're hopeful that the #newyear will continue to bring new scientific discoveries and treatments—here's to 2022! #Happynewyear #NewYear #newyear2022

[IFM Therapeutics @IFMThera]

Wishing you much health and happiness this holiday season! #HappyHolidays

[IFM Therapeutics @IFMThera]

Activation of the #NLRP1 #inflammasome leads to the induction of inflammatory cytokines and drives both rare and common diseases. Discover how we're developing potential drug candidates that target inflammasomes to treat #autoinflammatory and #autoimmunediseases:

[IFM Therapeutics @IFMThera]

Rare diseases such as #AGS and multiple self-healing palmoplantar carcinoma are associated with activation of #innateimmune pathways. See how we're working to develop therapies that precisely target the innate immune system and treat rare and #autoinflammatory diseases:

[IFM Therapeutics @IFMThera]

We're excited to announce the extension of our R&D collaboration agreement between @NovartisScience and IFM Due, an IFM subsidiary company, to develop #immunotherapies that inhibit the #cGAS-STING pathway. Read more: #innateimmune

[IFM Therapeutics @IFMThera]

How are we making advancements in therapies that target the #innateimmune system? We bring together key academic thought leaders & advisors in this field, along with an exceptionally talented group of #pharmaceutical #scientists & execs. Explore the team: https://t.co/u4qwSHoZCM

[IFM Therapeutics @IFMThera]

We're so grateful for our hardworking, dedicated team here at IFM and the ability to continue to enhance lives through science. From our IFM family to yours, #HappyThanksgiving! #thankful #Thanksgiving2021

[IFM Therapeutics @IFMThera]

New research finds that a subgroup of SLE patients fails to engage HIF-regulated metabolic and proteasomal pathways, causing the accumulation of mitochondria-containing red blood cells, eventually leading to #cGAS-STING-dependent #inflammation. Read more in our Science Spotlight:

[IFM Therapeutics @IFMThera]

#DYK Alzheimer's disease is the most common type of #dementia in the world? In a recent study, DNA damage in mice was increased in #AlzheimersDisease, and further, demonstrated that #cGAS–STING and NAD+ pathways are potential therapeutic targets: #AlzheimersDiseaseAwarenessMonth

[IFM Therapeutics @IFMThera]

Progress in understanding the #innateimmune system has allowed us to develop a leading portfolio of first-in-class small molecules that have the potential to treat patients with inflammation-driven diseases and #cancer. Explore more: https://t.co/GTUMvS0H49 #autoimmunedisease

[IFM Therapeutics @IFMThera]

Please help us welcome our new EVP, Head of Discovery to the IFM family! Stephanos Ioannidis has 18+ years’ experience in #oncology, #neuroscience and inflammation-focused drug development, and is an invaluable addition to our team! Excited to have you join us, Stephanos!